Ironvine Capital Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $466K | Hold |
16,600
| – | – | 0.05% | 49 |
|
|
2025
Q4 | $413K | Hold |
16,600
| – | – | 0.04% | 48 |
|
|
2025
Q3 | $423K | Hold |
16,600
| – | – | 0.04% | 48 |
|
|
2025
Q2 | $402K | Hold |
16,600
| – | – | 0.04% | 46 |
|
|
2025
Q1 | $421K | Hold |
16,600
| – | – | 0.05% | 46 |
|
|
2024
Q4 | $440K | Hold |
16,600
| – | – | 0.05% | 44 |
|
|
2024
Q3 | $480K | Sell |
16,600
-353
| -2% | -$10.3K | 0.05% | 43 |
|
|
2024
Q2 | $474K | Hold |
16,953
| – | – | 0.05% | 42 |
|
|
2024
Q1 | $470K | Buy |
16,953
+353
| +2% | +$9.79K | 0.05% | 42 |
|
|
2023
Q4 | $478K | Hold |
16,600
| – | – | 0.06% | 42 |
|
|
2023
Q3 | $551K | Hold |
16,600
| – | – | 0.07% | 41 |
|
|
2023
Q2 | $609K | Hold |
16,600
| – | – | 0.07% | 40 |
|
|
2023
Q1 | $677K | Hold |
16,600
| – | – | 0.09% | 41 |
|
|
2022
Q4 | $851K | Hold |
16,600
| – | – | 0.11% | 43 |
|
|
2022
Q3 | $726K | Hold |
16,600
| – | – | 0.1% | 45 |
|
|
2022
Q2 | $870K | Hold |
16,600
| – | – | 0.11% | 45 |
|
|
2022
Q1 | $859K | Hold |
16,600
| – | – | 0.09% | 45 |
|
|
2021
Q4 | $980K | Hold |
16,600
| – | – | 0.1% | 44 |
|
|
2021
Q3 | $714K | Hold |
16,600
| – | – | 0.08% | 46 |
|
|
2021
Q2 | $650K | Sell |
16,600
-58,452
| -78% | -$2.27M | 0.07% | 47 |
|
|
2021
Q1 | $2.72M | Hold |
75,052
| – | – | 0.32% | 40 |
|
|
2020
Q4 | $2.76M | Sell |
75,052
-4,053
| -5% | -$149K | 0.35% | 37 |
|
|
2020
Q3 | $2.75M | Hold |
79,105
| – | – | 0.35% | 35 |
|
|
2020
Q2 | $2.45M | Hold |
79,105
| – | – | 0.32% | 37 |
|
|
2020
Q1 | $2.45M | Buy |
79,105
+19,415
| +33% | +$662K | 0.38% | 34 |
|
|
2019
Q4 | $2.22M | Hold |
59,690
| – | – | 0.31% | 40 |
|
|
2019
Q3 | $2.06M | Hold |
59,690
| – | – | 0.3% | 41 |
|
|
2019
Q2 | $2.43M | Hold |
59,690
| – | – | 0.4% | 36 |
|
|
2019
Q1 | $2.4M | Hold |
59,690
| – | – | 0.45% | 34 |
|
|
2018
Q4 | $2.24M | Hold |
59,690
| – | – | 0.46% | 32 |
|
|
2018
Q3 | $2.5M | Hold |
59,690
| – | – | 0.51% | 32 |
|
|
2018
Q2 | $2.06M | Buy |
59,690
+22,144
| +59% | +$757K | 0.46% | 35 |
|
|
2018
Q1 | $1.26M | Buy |
37,546
+17,971
| +92% | +$618K | 0.3% | 50 |
|
|
2017
Q4 | $673K | Buy |
+19,575
| New | +$667K | 0.21% | 67 |
|
Other funds holding PFE
VCM
VPM
Ironvine Capital Partners's PFE Position: Q1 2026 in Review
Ironvine Capital Partners held its Pfizer (PFE) position steady in Q1 2026 at 16,600 shares worth $466K. The position accounts for 0.05% of the portfolio, ranked #49.
Ironvine Capital Partners first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.76M in Q4 2020. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Ironvine Capital Partners held 16,600 shares of Pfizer worth $466K as of Q1 2026.
- Ironvine Capital Partners left its Pfizer share count unchanged in Q1 2026.
- Pfizer made up 0.05% of Ironvine Capital Partners's portfolio in Q1 2026, its #49 holding.
- Ironvine Capital Partners first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- Ironvine Capital Partners's Pfizer position peaked at $2.76M in Q4 2020.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Ironvine Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.